BURLINGTON, ON, Oct. 11, 2012 /CNW/ - EKO International Inc. (EKNL-Pinksheets) is pleased announce an update on the product awareness campaign by NeuroVasc Clinical Inc. (NCI).
NCI is in negotiations with a company specializing in the supply of bi-directional electronic communication systems to the medical profession including physicians, diabetes education centres and health care providers for diabetics across Canada.
NCI's participation in this inter-active electronic communication system will make it possible for NCI's marketing team to deliver product knowledge, sales information and operating instructions in the use of the NC-Stat DPN check device (a point of care nerve conduction measurement tool essential in the early detection of peripheral neuropathy) to thousands of medical professionals across the country at the same time.
NCI will continue to support the Canadian and American Diabetes Associations' call for the annual testing of all diabetics for peripheral neuropathy, testing which medical professionals can accurately administer with the NC-Stat DPN check device supplied by NCI
NCI's goal is to continuously educate the health care community about the role FREMs can play in treating peripheral neuropathy and in preventing leg ulcers and their devastating complications.
The communication system is anticipated to be very useful in assisting thousands of health care providers to make the decision to either buy FREMS equipment to treat their patients or to direct their tested diabetic patients to the closest centres operating FREMS equipment.
Further details will be provided once negotiations are finalized.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by EKO International ("The Company") are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE: EKO INTERNATIONAL CORP.
For further information:
To contact the company by e-mail, please use email@example.com